2009 Investor Fact Sheet

Description

- World's most comprehensive and broadly based manufacturer of health care products
- Serves the Consumer, Pharmaceutical and Medical Devices and Diagnostics markets with a focus on research-based, technology-driven products

Consistent Performance

- 26 consecutive years of earnings increases adjusted for special items
- 48 consecutive years of dividends increases (includes April 2010 dividend increase)

	One Year	Five Years	Ten Years
Sales	(2.9)%	5.5%	8.5%
Diluted Earnings per Share [1]	(3.7)%	9.9%	12.6%
Dividend Growth	7.5%	12.0%	13.4%
Total Return to Shareholders	11.3%	2.9%	5.4%

[1] As reported, GAAP

Broadly Based/Exceptional Financial Strength

- Over 250 operating companies in 60 countries selling products throughout the world (50% of sales outside of U.S.)
- Sales split among Consumer, Pharmaceutical and Medical Devices and Diagnostics business segments
- More than 100 drugs marketed; 37 drugs over $50 million; 25 drugs over $100 million; 7 drugs over $1 billion
- One of a few U.S. industrial companies that still commands a Triple A credit rating by both Standard & Poor's and Moody's credit rating agencies
- Generated record annual free cash flow in 2009 of $14.2





Worldwide Market Leadership

- Largest Medical Device company
- 8th largest Pharmaceutical company globally
- 4th largest Biotech company globally
- Leadership Positions in Major Markets:
  - Anti-Anemia
  - Antipsychotics (Injectables)
  - Anti - TNF
  - Baby & Kids Care
  - Blood Glucose Monitoring
  - Blood Screening & Typing
  - Breast Aesthetics
  - Coronary Stents
  - Disposable Contact Lenses
  - Electrophysiology diagnostics & catheters
  - Insulin Delivery
  - Lo-Cal Sweeteners
  - Minimally Invasive Surgery
  - Oral Rinses
  - Orthopaedics
  - Over-the-Counter Pharmaceuticals
  - Psychostimulants
  - Quinolone Anti-Infective
  - Sanitary Protection
  - Sutures
  - Wound Care
- Approximately 70% of sales are derived from products/businesses that have a #1 or #2 global market share position

Please visit our Home Page on the Internet at http://www.jnj.com for requests for **Company Reports**, including the 2009 Annual Report and SEC filings. Questions regarding stock holdings and the **Dividend Reinvestment Plan**, should be directed to: Computershare Trust Company,N.A. Phone (800) 328-9033



This chart provides a comparison of cumulative total shareholder return for an investment in Johnson & Johnson Common Stock as of December 31, 2004 to a similar investment. Assuming dividends were reinvested, a $100.00 investment in Johnson & Johnson would have grown to $115.55 as of December 31, 2009. This compares to a value of $102.11 for the S&P 500 Stock Index and $113.68 for the S&P Pharmaceutical Index and $102.06 for the S&P Health Care Equipment Index.
Source: Bloomberg







Strong Commitment to New Product Development

- $7.0 billion in Research & Development spending in 2009
- Numerous external alliances and collaborations entered into annually
- Approximately 25% of products sold in 2009 introduced in last 5 years

Well Positioned for Future Growth

- Solid pipeline of new and innovative products
- U.S. demographics point to high growth in health care industry
- Broad geographic reach provides ability to rapidly introduce new products in markets around the world
- Focus on products which reduce the cost of health care
- Management based on a core set of Strategic Principles: Broadly based in human healthcare, decentralized management structure, long term focus and Credo based decision making.

Investor Information

NYSE Symbol: JNJ

For additional information, contact:
Investor Relations Department
One Johnson & Johnson Plaza
New Brunswick, NJ 08933
Voice: (800) 950-5089
Fax: (732) 524-3867

Press releases, including earnings reports, are available via web access: http://www.jnj.com

© Johnson & Johnson 2010